Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics
Identifieur interne : 002C73 ( Main/Exploration ); précédent : 002C72; suivant : 002C74Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics
Auteurs : C. V. Sapan ; H. M. Reisner [États-Unis] ; R. L. Lundblad [États-Unis]Source :
- Vox Sanguinis [ 0042-9007 ] ; 2007-04.
English descriptors
- Teeft :
- Assay, Autoimmune diseases, Autoimmune thrombocytopenic purpura, Blackwell publishing, Cdna, Cdna probes, Cell types, Chapel hill, Chronic demyelinating polyneuropathy, Clin, Clinical effectiveness, Commercial ivig preparations, Cytokine, Direct neutralization, Drotrecogin alfa, Expensive therapy, Further understanding, Gene, Gene expression, Gene expression analysis, Host responses, Human neutrophils, Human plasma, Human plasma fractionation, Human serum, Idiopathic, Idiopathic thrombocytopenic purpura, Immune, Immune cell function, Immune cell systems, Immune deviation, Immune system cells, Immune tolerance, Immunoglobulin, Immunol, Immunologic studies, Immunomodulation, Immunomodulation drug, Immunomodulatory activity, Immunotherapeutic drug, Infectious disease, Intravenous, Intravenous immunoglobulin, Intravenous immunoglobulin preparations, Intravenous immunoglobulins, Ivig, Joint council, Journal compilation, Kawasaki, Kawasaki disease, Lactated solution, Lancet neurol, Marcel dekker, Measure gene expression, Microarray, Microarray analysis, Microarray experiments, Microarray studies, Microarray study, Microarray technology, Microarrays, Mrna expression, Neutralizing antibodies, Neutrophil, Oligonucleotide, Other studies, Peripheral blood, Pilot study, Protein expression, Protein microarray, Protein microarray technology, Protein microarrays, Proteomic analysis, Purpura, Rheumatoid arthritis, Sanguinis, Serial analysis, Serum gamma globulin, Serum sickness, Several studies, Severe sepsis, Study gene expression, Surrogate assays, Syndrome, Thrombocytopenic, Transcriptional analysis, Trends genet, Variable region.
Abstract
Background and Objectives Intravenous immunoglobulin (IVIG) is used for an increasingly diverse number of therapeutic applications as an immunomodulation drug. Although it has demonstrated therapeutic effectiveness, the mechanism of action of IVIG in these disorders is poorly understood; this lack of understanding complicates rational clinical application and reimbursement for ‘off‐label’ use. Materials and Methods Selected literature on the clinical use of IVIG as an immunomodulation drug is reviewed. We present a brief description of DNA microarray and protein microarray technology and the application of such technologies to the study of immune system cells. The several studies on the application of DNA microarray technology to study gene expression in response to IVIG are presented. Results There is increasing data on the use of DNA microarray and protein microarray technology to study gene expression in immune system cells including T cells, B cells, macrophages, and leucocytes. There is less information on the effect of IVIG on gene expression in immune system cells. However, there is sufficient information available to suggest that this is a practical approach with the caveat that such work will require careful experimental design and clear definition of the normal population. Conclusions DNA and protein microarray assays can be used to (i) provide rational indications for the clinical use of IVIG, (ii) provide for specific analysis of raw material and end product IVIG in screening for content related to immunomodulation, and (iii) accelerate the development of next generation products which would be more focused and/or targeted therapeutics.
Url:
DOI: 10.1111/j.1423-0410.2006.00877.x
Affiliations:
- États-Unis
- Caroline du Nord
- Chapel Hill (Caroline du Nord)
- Université de Caroline du Nord à Chapel Hill
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C60
- to stream Istex, to step Curation: 001C60
- to stream Istex, to step Checkpoint: 000926
- to stream Main, to step Merge: 002C99
- to stream Main, to step Curation: 002C73
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics</title><author><name sortKey="Sapan, C V" sort="Sapan, C V" uniqKey="Sapan C" first="C. V." last="Sapan">C. V. Sapan</name></author><author><name sortKey="Reisner, H M" sort="Reisner, H M" uniqKey="Reisner H" first="H. M." last="Reisner">H. M. Reisner</name></author><author><name sortKey="Lundblad, R L" sort="Lundblad, R L" uniqKey="Lundblad R" first="R. L." last="Lundblad">R. L. Lundblad</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7AABB996F8D233C19171EAFD9B4B3ADAC20586D0</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1423-0410.2006.00877.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-2ZT4MD3R-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001C60</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C60</idno><idno type="wicri:Area/Istex/Curation">001C60</idno><idno type="wicri:Area/Istex/Checkpoint">000926</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000926</idno><idno type="wicri:doubleKey">0042-9007:2007:Sapan C:antibody:therapy:ivig</idno><idno type="wicri:Area/Main/Merge">002C99</idno><idno type="wicri:Area/Main/Curation">002C73</idno><idno type="wicri:Area/Main/Exploration">002C73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics</title><author><name sortKey="Sapan, C V" sort="Sapan, C V" uniqKey="Sapan C" first="C. V." last="Sapan">C. V. Sapan</name></author><author><name sortKey="Reisner, H M" sort="Reisner, H M" uniqKey="Reisner H" first="H. M." last="Reisner">H. M. Reisner</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599</wicri:regionArea><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Lundblad, R L" sort="Lundblad, R L" uniqKey="Lundblad R" first="R. L." last="Lundblad">R. L. Lundblad</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599</wicri:regionArea><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Vox Sanguinis</title><title level="j" type="alt">VOX SANGUINIS</title><idno type="ISSN">0042-9007</idno><idno type="eISSN">1423-0410</idno><imprint><biblScope unit="vol">92</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="197">197</biblScope><biblScope unit="page" to="205">205</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-04">2007-04</date></imprint><idno type="ISSN">0042-9007</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0042-9007</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Assay</term><term>Autoimmune diseases</term><term>Autoimmune thrombocytopenic purpura</term><term>Blackwell publishing</term><term>Cdna</term><term>Cdna probes</term><term>Cell types</term><term>Chapel hill</term><term>Chronic demyelinating polyneuropathy</term><term>Clin</term><term>Clinical effectiveness</term><term>Commercial ivig preparations</term><term>Cytokine</term><term>Direct neutralization</term><term>Drotrecogin alfa</term><term>Expensive therapy</term><term>Further understanding</term><term>Gene</term><term>Gene expression</term><term>Gene expression analysis</term><term>Host responses</term><term>Human neutrophils</term><term>Human plasma</term><term>Human plasma fractionation</term><term>Human serum</term><term>Idiopathic</term><term>Idiopathic thrombocytopenic purpura</term><term>Immune</term><term>Immune cell function</term><term>Immune cell systems</term><term>Immune deviation</term><term>Immune system cells</term><term>Immune tolerance</term><term>Immunoglobulin</term><term>Immunol</term><term>Immunologic studies</term><term>Immunomodulation</term><term>Immunomodulation drug</term><term>Immunomodulatory activity</term><term>Immunotherapeutic drug</term><term>Infectious disease</term><term>Intravenous</term><term>Intravenous immunoglobulin</term><term>Intravenous immunoglobulin preparations</term><term>Intravenous immunoglobulins</term><term>Ivig</term><term>Joint council</term><term>Journal compilation</term><term>Kawasaki</term><term>Kawasaki disease</term><term>Lactated solution</term><term>Lancet neurol</term><term>Marcel dekker</term><term>Measure gene expression</term><term>Microarray</term><term>Microarray analysis</term><term>Microarray experiments</term><term>Microarray studies</term><term>Microarray study</term><term>Microarray technology</term><term>Microarrays</term><term>Mrna expression</term><term>Neutralizing antibodies</term><term>Neutrophil</term><term>Oligonucleotide</term><term>Other studies</term><term>Peripheral blood</term><term>Pilot study</term><term>Protein expression</term><term>Protein microarray</term><term>Protein microarray technology</term><term>Protein microarrays</term><term>Proteomic analysis</term><term>Purpura</term><term>Rheumatoid arthritis</term><term>Sanguinis</term><term>Serial analysis</term><term>Serum gamma globulin</term><term>Serum sickness</term><term>Several studies</term><term>Severe sepsis</term><term>Study gene expression</term><term>Surrogate assays</term><term>Syndrome</term><term>Thrombocytopenic</term><term>Transcriptional analysis</term><term>Trends genet</term><term>Variable region</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background and Objectives Intravenous immunoglobulin (IVIG) is used for an increasingly diverse number of therapeutic applications as an immunomodulation drug. Although it has demonstrated therapeutic effectiveness, the mechanism of action of IVIG in these disorders is poorly understood; this lack of understanding complicates rational clinical application and reimbursement for ‘off‐label’ use. Materials and Methods Selected literature on the clinical use of IVIG as an immunomodulation drug is reviewed. We present a brief description of DNA microarray and protein microarray technology and the application of such technologies to the study of immune system cells. The several studies on the application of DNA microarray technology to study gene expression in response to IVIG are presented. Results There is increasing data on the use of DNA microarray and protein microarray technology to study gene expression in immune system cells including T cells, B cells, macrophages, and leucocytes. There is less information on the effect of IVIG on gene expression in immune system cells. However, there is sufficient information available to suggest that this is a practical approach with the caveat that such work will require careful experimental design and clear definition of the normal population. Conclusions DNA and protein microarray assays can be used to (i) provide rational indications for the clinical use of IVIG, (ii) provide for specific analysis of raw material and end product IVIG in screening for content related to immunomodulation, and (iii) accelerate the development of next generation products which would be more focused and/or targeted therapeutics.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li></region><settlement><li>Chapel Hill (Caroline du Nord)</li></settlement><orgName><li>Université de Caroline du Nord à Chapel Hill</li></orgName></list><tree><noCountry><name sortKey="Sapan, C V" sort="Sapan, C V" uniqKey="Sapan C" first="C. V." last="Sapan">C. V. Sapan</name></noCountry><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Reisner, H M" sort="Reisner, H M" uniqKey="Reisner H" first="H. M." last="Reisner">H. M. Reisner</name></region><name sortKey="Lundblad, R L" sort="Lundblad, R L" uniqKey="Lundblad R" first="R. L." last="Lundblad">R. L. Lundblad</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7AABB996F8D233C19171EAFD9B4B3ADAC20586D0
|texte= Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics
}}
| This area was generated with Dilib version V0.6.33. |  |